Short-term Effects of Transdermal Estradiol on Female COVID-19 Patients
Status:
Completed
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
The goal of this randomized placebo-controlled study is to investigate the short-term effects
of transdermal estrogen therapy on postmenopausal women with COVID-19 disease.
The main question[s] it aims to answer are:
- the clinical outcomes with adding estrogen treatment to conventional therapy of Covid-19
disease
- the biochemical outcomes with adding estrogen treatment to conventional therapy of
Covid-19 disease
All participants received favipiravir for a week according to the national guidelines
published by the Health Ministry of Turkish Republic at that time.
As an intervention, transdermal estradiol patch (7.8 mg patch/week) was applied for 14 days
on the upper buttock of the patients in experimental arm. As a placebo, hydrogel patch
(adhesive hydrogel patch/week) was applied to the female patients for 14 days.
Researchers compared experimental and control groups to see if the impact of adding estrogen
on the clinical course of Covid-19 disease
Phase:
Phase 2
Details
Lead Sponsor:
Istanbul University - Cerrahpasa (IUC)
Collaborators:
Karakoy Rotary Club Rebul Pharmacy Turkish Menopause and Osteoporosis Society